Enveric Biosciences Net Income
| ENVB Stock | USD 2.91 0.16 5.21% |
As of the 2nd of February, Enveric Biosciences shows the Standard Deviation of 13.62, variance of 185.49, and Mean Deviation of 7.28. Enveric Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Enveric Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.7579 | Revenue | Earnings Share (119.64) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -44.1 M | -41.9 M | |
| Net Loss | (205.63) | (215.91) | |
| Net Income Per E B T | 1.15 | 1.03 |
Enveric | Net Income | Build AI portfolio with Enveric Stock |
Analyzing Enveric Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Enveric Biosciences's current valuation and future prospects.
Latest Enveric Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Enveric Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Enveric Biosciences financial statement analysis. It represents the amount of money remaining after all of Enveric Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Enveric Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enveric Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Enveric Net Income Regression Statistics
| Arithmetic Mean | (8,134,227) | |
| Coefficient Of Variation | (147.67) | |
| Mean Deviation | 7,399,185 | |
| Median | (5,603,975) | |
| Standard Deviation | 12,011,584 | |
| Sample Variance | 144.3T | |
| Range | 49M | |
| R-Value | (0.41) | |
| Mean Square Error | 128.6T | |
| R-Squared | 0.16 | |
| Significance | 0.11 | |
| Slope | (963,745) | |
| Total Sum of Squares | 2308.5T |
Enveric Net Income History
Other Fundumenentals of Enveric Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Enveric Biosciences Net Income component correlations
Enveric Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Enveric Biosciences is extremely important. It helps to project a fair market value of Enveric Stock properly, considering its historical fundamentals such as Net Income. Since Enveric Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enveric Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enveric Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. Projected growth potential of Enveric fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enveric Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (119.64) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
Understanding Enveric Biosciences requires distinguishing between market price and book value, where the latter reflects Enveric's accounting equity. The concept of intrinsic value—what Enveric Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Enveric Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Enveric Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enveric Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Enveric Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Enveric Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enveric Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enveric Biosciences.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Enveric Biosciences on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Enveric Biosciences or generate 0.0% return on investment in Enveric Biosciences over 90 days. Enveric Biosciences is related to or competes with Jasper Therapeutics, Onconetix, ZyVersa Therapeutics, Indaptus Therapeutics, Scisparc, Azitra, and Biomotion Sciences. Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care More
Enveric Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enveric Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enveric Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 121.83 | |||
| Value At Risk | (16.57) | |||
| Potential Upside | 14.08 |
Enveric Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enveric Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enveric Biosciences' standard deviation. In reality, there are many statistical measures that can use Enveric Biosciences historical prices to predict the future Enveric Biosciences' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.26) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enveric Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enveric Biosciences February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 7.28 | |||
| Coefficient Of Variation | (2,498) | |||
| Standard Deviation | 13.62 | |||
| Variance | 185.49 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 121.83 | |||
| Value At Risk | (16.57) | |||
| Potential Upside | 14.08 | |||
| Skewness | 2.11 | |||
| Kurtosis | 15.49 |
Enveric Biosciences Backtested Returns
Enveric Biosciences secures Sharpe Ratio (or Efficiency) of -0.0191, which denotes the company had a -0.0191 % return per unit of risk over the last 3 months. Enveric Biosciences exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Enveric Biosciences' Standard Deviation of 13.62, variance of 185.49, and Mean Deviation of 7.28 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.1, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enveric Biosciences will likely underperform. At this point, Enveric Biosciences has a negative expected return of -0.26%. Please make sure to confirm Enveric Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Enveric Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.11 |
Insignificant predictability
Enveric Biosciences has insignificant predictability. Overlapping area represents the amount of predictability between Enveric Biosciences time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enveric Biosciences price movement. The serial correlation of 0.11 indicates that less than 11.0% of current Enveric Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Enveric Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Enveric Biosciences reported net income of (9.57 Million). This is 102.81% lower than that of the Biotechnology sector and 113.67% lower than that of the Health Care industry. The net income for all United States stocks is 101.68% higher than that of the company.
Enveric Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enveric Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enveric Biosciences could also be used in its relative valuation, which is a method of valuing Enveric Biosciences by comparing valuation metrics of similar companies.Enveric Biosciences is currently under evaluation in net income category among its peers.
Enveric Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Enveric Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Enveric Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Enveric Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Enveric Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Enveric Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Enveric Biosciences' value.| Shares | Wells Fargo & Co | 2025-06-30 | 2.0 | Group One Trading, Lp | 2025-06-30 | 1.0 | Jones Financial Companies Lllp | 2025-06-30 | 1.0 | Fmr Inc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Headlands Technologies Llc | 2025-06-30 | 0.0 | Nelson, Van Denburg & Campbell Wealth Management Group, Llc | 2025-03-31 | 0.0 | Hrt Financial Llc | 2025-06-30 | 0.0 | Advisorshares Investments, Llc | 2025-06-30 | 103.7 K | Renaissance Technologies Corp | 2025-06-30 | 37 K | Geode Capital Management, Llc | 2025-06-30 | 28.2 K |
Enveric Fundamentals
| Return On Equity | -2.62 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 510.73 K | ||||
| Shares Outstanding | 518.3 K | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 6.93 % | ||||
| Number Of Shares Shorted | 67.69 K | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 0.08 X | ||||
| Gross Profit | 8.15 M | ||||
| EBITDA | (9.23 M) | ||||
| Net Income | (9.57 M) | ||||
| Cash And Equivalents | 18.01 M | ||||
| Cash Per Share | 11.44 X | ||||
| Total Debt | 1.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.33 X | ||||
| Book Value Per Share | 8.66 X | ||||
| Cash Flow From Operations | (7.73 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (119.64) X | ||||
| Target Price | 10.0 | ||||
| Beta | 0.28 | ||||
| Market Capitalization | 2.83 M | ||||
| Total Asset | 3.08 M | ||||
| Retained Earnings | (106.07 M) | ||||
| Working Capital | 1.24 M | ||||
| Net Asset | 3.08 M |
About Enveric Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enveric Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enveric Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enveric Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. Projected growth potential of Enveric fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enveric Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (119.64) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
Understanding Enveric Biosciences requires distinguishing between market price and book value, where the latter reflects Enveric's accounting equity. The concept of intrinsic value—what Enveric Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Enveric Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Enveric Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enveric Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Enveric Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.